Abrogation of the Circadian Nuclear Receptor REV-ERBα Exacerbates 6-Hydroxydopamine-Induced Dopaminergic Neurodegeneration

Parkinson’s disease (PD) is a neurodegenerative disease characterized by progressive degeneration of dopaminergic (DAergic) neurons, particularly in the substantia nigra (SN). Although circadian dysfunction has been suggested as one of the pathophysiological risk factors for PD, the exact molecular link between the circadian clock and PD remains largely unclear. We have recently demonstrated that REV-ERBα, a circadian nuclear receptor, serves as a key molecular link between the circadian and DAergic systems. It competitively cooperates with NURR1, another nuclear receptor required for the optimal development and function of DA neurons, to control DAergic gene transcription. Considering our previous findings, we hypothesize that REV-ERBα may have a role in the onset and/or progression of PD. In the present study, we therefore aimed to elucidate whether genetic abrogation of REV-ERBα affects PD-related phenotypes in a mouse model of PD produced by a unilateral injection of 6-hydroxydopamine (6-OHDA) into the dorsal striatum. REV-ERBα deficiency significantly exacerbated 6-OHDA-induced motor deficits as well as DAergic neuronal loss in the vertebral midbrain including the SN and the ventral tegmental area. The exacerbated DAergic degeneration likely involves neuroinflammation-mediated neurotoxicity. The Rev-erbα knockout mice showed prolonged microglial activation in the SN along with the overproduction of interleukin 1β, a pro-inflammatory cytokine, in response to 6-OHDA. In conclusion, the present study demonstrates for the first time that genetic abrogation of REV-ERBα can increase vulnerability of DAergic neurons to neurotoxic insults, such as 6-OHDA, thereby implying that its normal function may be beneficial for maintaining DAergic neuron populations during PD progression.

[1]  Sooyoung Chung,et al.  Small Molecule Modulators of the Circadian Molecular Clock With Implications for Neuropsychiatric Diseases , 2019, Front. Mol. Neurosci..

[2]  M. Zordan,et al.  Circadian Rhythm Abnormalities in Parkinson’s Disease from Humans to Flies and Back , 2018, International journal of molecular sciences.

[3]  S. Merali,et al.  Circadian rhythm dysfunction: a novel environmental risk factor for Parkinson’s disease , 2017, Molecular Psychiatry.

[4]  P. Franken,et al.  Altered Sleep Homeostasis in Rev-erbα Knockout Mice. , 2016, Sleep.

[5]  P. Chan,et al.  Association of ARNTL and PER1 genes with Parkinson's disease: a case-control study of Han Chinese , 2015, Scientific Reports.

[6]  S. Maier,et al.  Microglia inflammatory responses are controlled by an intrinsic circadian clock , 2015, Brain, Behavior, and Immunity.

[7]  R. Barker,et al.  'The clocks that time us'—circadian rhythms in neurodegenerative disorders , 2014, Nature Reviews Neurology.

[8]  A. Roberts,et al.  Pharmacological Targeting of the Mammalian Clock Regulates Sleep Architecture and Emotional Behavior , 2014, Nature Communications.

[9]  M. Lazar,et al.  Nuclear receptor Rev-erbα: up, down, and all around , 2014, Trends in Endocrinology & Metabolism.

[10]  Sooyoung Chung,et al.  Impact of Circadian Nuclear Receptor REV-ERBα on Midbrain Dopamine Production and Mood Regulation , 2014, Cell.

[11]  R. Barker,et al.  Sleep and circadian rhythm regulation in early Parkinson disease. , 2014, JAMA neurology.

[12]  H. Kennedy,et al.  Alteration of Daily and Circadian Rhythms following Dopamine Depletion in MPTP Treated Non-Human Primates , 2014, PloS one.

[13]  D. Holtzman,et al.  Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration. , 2013, The Journal of clinical investigation.

[14]  J. Honnorat,et al.  Mapping and kinetics of microglia/neuron cell‐to‐cell contacts in the 6‐OHDA murine model of Parkinson's disease , 2013, Glia.

[15]  A. Chawla,et al.  Circadian Gene Bmal1 Regulates Diurnal Oscillations of Ly6Chi Inflammatory Monocytes , 2013, Science.

[16]  J. Eeckhoute,et al.  Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy , 2013, Nature Medicine.

[17]  B. Cho,et al.  Relationship between Microglial Activation and Dopaminergic Neuronal Loss in 6-OHDA-induced Parkinsonian Animal Model , 2013 .

[18]  S. Ohdo,et al.  A Disruption Mechanism of the Molecular Clock in a MPTP Mouse Model of Parkinson’s Disease , 2013, NeuroMolecular Medicine.

[19]  J. Takahashi,et al.  Regulation of Circadian Behavior and Metabolism by Synthetic REV-ERB Agonists , 2012, Nature.

[20]  A. Loudon,et al.  The nuclear receptor REV-ERBα mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines , 2011, Proceedings of the National Academy of Sciences.

[21]  C. Colwell,et al.  Circadian dysfunction in a mouse model of Parkinson's disease , 2011, Experimental Neurology.

[22]  Woong Sun,et al.  Dissociation of Progressive Dopaminergic Neuronal Death and Behavioral Impairments by Bax Deletion in a Mouse Model of Parkinson's Diseases , 2011, PloS one.

[23]  D. Kojetin,et al.  Identification of SR8278, a synthetic antagonist of the nuclear heme receptor REV-ERB. , 2011, ACS chemical biology.

[24]  D. Finn,et al.  Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat , 2011, Neuroscience.

[25]  D. Bechtold,et al.  Circadian dysfunction in disease. , 2010, Trends in pharmacological sciences.

[26]  M. Goldberg,et al.  Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention , 2010, Neurobiology of Disease.

[27]  Erik D. Herzog,et al.  A circadian clock in macrophages controls inflammatory immune responses , 2009, Proceedings of the National Academy of Sciences.

[28]  D. Dexter,et al.  Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6‐hydroxydopamine model of Parkinson’s disease , 2009, Journal of neurochemistry.

[29]  E. Hirsch,et al.  Neuroinflammation in Parkinson's disease: a target for neuroprotection? , 2009, The Lancet Neurology.

[30]  A. Hartmann,et al.  Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and α-synuclein-deleted mice , 2008, Experimental Neurology.

[31]  S. Dunnett,et al.  Comparison of incremental and accelerating protocols of the rotarod test for the assessment of motor deficits in the 6-OHDA model , 2006, Journal of Neuroscience Methods.

[32]  C. Ferrari,et al.  Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1β in the substantia nigra , 2006, Neurobiology of Disease.

[33]  C. Tanner,et al.  Excessive daytime sleepiness and subsequent development of Parkinson disease , 2005, Neurology.

[34]  Nicolas Cermakian,et al.  Differential Control of Bmal1 Circadian Transcription by REV-ERB and ROR Nuclear Receptors , 2005, Journal of biological rhythms.

[35]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[36]  Ueli Schibler,et al.  The Orphan Nuclear Receptor REV-ERBα Controls Circadian Transcription within the Positive Limb of the Mammalian Circadian Oscillator , 2002, Cell.

[37]  Peter Riederer,et al.  Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients , 1995, Neuroscience Letters.

[38]  P. Riederer,et al.  Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients , 1994, Neuroscience Letters.

[39]  W. H. Oertel,et al.  Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat , 1994, Neuroscience.

[40]  Minoru Harada,et al.  Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients , 1994, Neuroscience Letters.

[41]  P. Mcgeer,et al.  Microglial response to 6-hydroxydopamine-induced substantia nigra lesions , 1989, Brain Research.

[42]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[43]  C. Comella Sleep disturbances and excessive daytime sleepiness in Parkinson disease: an overview. , 2006, Journal of neural transmission. Supplementum.

[44]  A. Schapira,et al.  Genetic and environmental factors in the cause of Parkinson's disease , 2003, Annals of neurology.